Product attributes
NAGLAZYME® (galsulfase) is an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI). Naglazyme provides a recombinant version of the enzyme missing in individuals diagnosed with MPS VI.
Severe and life-threatening allergic reactions can occur during NAGLAZYME (galsulfase) infusions and up to 24 hours after infusion. Typical signs of an allergic reaction include shock, difficulty breathing, wheezing, swelling of the throat, and low blood pressure. Please see the Important Safety Information below and Full Prescribing Information.
MPS VI, also known as Maroteaux-Lamy Syndrome, is an inherited lysosomal storage disorder caused by the deficiency of an enzyme normally required for the breakdown of glycosaminoglycans (GAGs). If the enzyme is not present in sufficient quantities, the normal breakdown of GAGs is incomplete or blocked. The cell is unable to excrete the GAG residues, which then accumulate in the lysosomes of the cell. This accumulation disrupts the cell’s normal functioning and gives rise to the physical manifestations of the disease. Only about 1,100 people in the world are thought to live with MPS VI.
